Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May;99(5):1001-1004.
doi: 10.1002/ajh.27265. Epub 2024 Feb 25.

CALR-mutated patients with low allele burden represent a specific subtype of essential thrombocythemia: A study on behalf of FIM and GBMHM

Laura Aubin  1   2   3 , Rúben Vilas Boas  4 , Rafael Daltro De Oliveira  5 , Valoris Le Brun  6 , Marion Divoux  7   8 , Jérôme Rey  9 , Olivier Mansier  10   11 , Jean-Christophe Ianotto  12 , Cédric Pastoret  3 , Anne Desmares  3 , Anne Murati  13 , Véronique de Mas  14 , Suzanne Tavitian  15 , François Girodon  4 , Juliette Soret Dulphy  5 , Nabih Maslah  16 , Valérie Goncalves Monteiro  17 , Françoise Boyer  18 , Corentin Orvain  18 , Dana Ranta  7 , Émilie Cayssials  19 , Lenaig Le Clech  20 , Christophe Nicol  21 , Camille Rottier  22 , Teresa Botin Lopez  23 , Brice Castel  24 , Patrick Rispal  25 , Guillaume Beziat  26 , Charles Bescond  27 , Kamel Laribi  28 , Lina Benajiba  5 , Valérie Ugo  1 , Eric Lippert  6   29 , Laurane Cottin  1 , Damien Luque Paz  1
Affiliations
Free article

CALR-mutated patients with low allele burden represent a specific subtype of essential thrombocythemia: A study on behalf of FIM and GBMHM

Laura Aubin et al. Am J Hematol. 2024 May.
Free article

Abstract

A low allele burden (i.e., <20%) of the CALR driver mutation is found in 10.8% of CALR-mutated MPNs, mostly in essential thrombocythemia, and correlates with a milder phenotype and a more indolent evolution compared to patients with an allele burden ≥20%.

PubMed Disclaimer

References

REFERENCES

    1. Luque Paz D, Kralovics R, Skoda RC. Genetic basis and molecular profiling in myeloproliferative neoplasms. Blood. 2023;141:1909‐1921. doi:10.1182/blood.2022017578
    1. Nienhold R, Ashcroft P, Zmajkovic J, et al. MPN patients with low mutant JAK2 allele burden show late expansion restricted to erythroid and megakaryocytic lineages. Blood. 2020;136:2591‐2595. doi:10.1182/blood.2019002943
    1. El‐Khoury M, Cabagnols X, Mosca M, et al. Different impact of calreticulin mutations on human hematopoiesis in myeloproliferative neoplasms. Oncogene. 2020;39:5323‐5337. doi:10.1038/s41388‐020‐1368‐3
    1. Pietra D, Rumi E, Ferretti VV, et al. Differential clinical effects of different mutation subtypes in CALR‐mutant myeloproliferative neoplasms. Leukemia. 2016;30:431‐438. doi:10.1038/leu.2015.277
    1. Guglielmelli P, Maccari C, Sordi B, et al. Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis. Blood Cancer J. 2023;13:21. doi:10.1038/s41408‐023‐00786‐x

Publication types

LinkOut - more resources